Roman Kasianov
Covers AI in drug discovery, digital pathology, and translational R&D, editor of "Where Tech Meets Bio"; oversees company profiles, partnerships, and core operations at BiopharmaTrend.
Recent articles from Roman
Insilico Medicine Goes for Hong Kong IPO, Aims to Raise $292M
AI drug developer Insilico Medicine has returned to the Hong Kong public markets with an updated IPO prospectus, targeting about $292 million in proceeds. The submission marks the company’s fourth bid to list on the Hong Kong Stock Exchange, and …
Bioptimus Releases Multimodal "World Model" For Biology Covering Histology, Transcriptomics, And Clinical Data
Bioptimus has announced M-Optimus, a foundation model trained on multimodal biomedical data including histology, bulk and spatial transcriptomics, and clinical records, aiming to simulate biological processes across cells, tissues, and patients. The model was trained on a proprietary dataset encompassing …
Latent Labs Announces AI-Generated Antibodies with Low Immune Activation
Latent Labs, which emerged from stealth earlier this year with $50 million in funding, has announced Latent-X2, a generative AI model that produces antibody and peptide drug candidates with preclinical-like developability from the outset, aiming to reduce or eliminate …
Insilico Medicine Reports AI-Designed PROTAC That Degrades and Inhibits PKMYT1
This month, Insilico Medicine has published a paper in Nature Communications describing an AI-generated PROTAC that targets PKMYT1, a kinase linked to synthetic lethality in cancers with CCNE1 amplification or mutations in FBXW7 and PPP2R1A. Insilico presents the work as …
Lilly Taps Insilico Medicine's AI in $100M Drug Discovery Collaboration
Insilico Medicine has entered a research and licensing collaboration with Eli Lilly, expanding their existing partnership to jointly discover novel therapeutics using Insilico’s Pharma.AI platform. The collaboration builds on a prior software licensing agreement signed in 2023, under which Lilly …
Insilico Medicine Presents Eight Oral Cardiometabolic Drug Candidates Designed With AI
On November 7, 2025 at BIO-Europe, Insilico Medicine disclosed eight oral small-molecule programs for cardiometabolic diseases discovered with its Pharma.AI platform. The portfolio spans lead identification to IND-enabling and targets GLP-1R, GIPR, dual amylin/calcitonin receptors (DACRA), APJ, Lp(a), NLRP3, and …
Recursion Completes Whole-Genome Microglia Map With Roche and Genentech
Recursion announces the acceptance of its whole-genome Microglia Map by Roche and Genentech, marking the culmination of a three-year collaboration focused on decoding microglial cell biology.
The milestone triggered a $30 million payment to Recursion, bringing total cash inflows from …
Flagship's New AI Covalent Chemistry Startup; $50M Commitment and Pfizer Program
Flagship Pioneering announced Expedition Medicines after three years of internal development, committing $50 million to scale a quantum-chemistry-driven generative platform for covalent small-molecule discovery, with programs in oncology, immunology, and other well-defined diseases. Expedition, founded in 2022, has begun …
Iambic’s AI-Designed Cancer Drug Shows Early Clinical Activity
Iambic Therapeutics presented new data from its ongoing Phase 1/1b trial of IAM1363 at the 2025 ESMO Congress, showing anti-tumor activity in heavily pretreated patients with HER2-driven cancers, including those previously treated with T-DXd and tucatinib. The AI-designed small molecule …
AstraZeneca and AI-Powered Immune Mapping Company Immunai Sign Up To $85M IBD Target Agreement
Immunai has signed an agreement with AstraZeneca to develop a therapeutic target for inflammatory bowel disease (IBD), marking a shift from their existing oncology-focused collaboration started in 2022. The deal is valued at up to $85 million and grants …